As a new predictive factor for efficacy, tumor-infiltrating lymphocytes have been reported to correlate significantly with the response to ICI, more than does tumor PD-L1 expression, in patients with NSCLC who have low PD-L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.